- Home
- OPK vs AUPH Comparison
OPK vs AUPH Comparison
Compare OPK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- AUPH
- Stock Information
- Founded
- OPK 2007
- AUPH 1993
- Country
- OPK United States
- AUPH Canada
- Employees
- OPK N/A
- AUPH N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- AUPH Health Care
- Exchange
- OPK Nasdaq
- AUPH Nasdaq
- Market Cap
- OPK 1.0B
- AUPH 1.4B
- IPO Year
- OPK 1995
- AUPH 1999
- Fundamental
- Price
- OPK $1.51
- AUPH $12.89
- Analyst Decision
- OPK Buy
- AUPH Strong Buy
- Analyst Count
- OPK 4
- AUPH 3
- Target Price
- OPK $2.75
- AUPH $12.00
- AVG Volume (30 Days)
- OPK 2.1M
- AUPH 1.5M
- Earning Date
- OPK 11-06-2025
- AUPH 11-06-2025
- Dividend Yield
- OPK N/A
- AUPH N/A
- EPS Growth
- OPK N/A
- AUPH N/A
- EPS
- OPK N/A
- AUPH 0.42
- Revenue
- OPK $664,029,000.00
- AUPH $260,111,000.00
- Revenue This Year
- OPK N/A
- AUPH $16.92
- Revenue Next Year
- OPK $0.84
- AUPH $14.43
- P/E Ratio
- OPK N/A
- AUPH $29.26
- Revenue Growth
- OPK N/A
- AUPH 25.59
- 52 Week Low
- OPK $1.11
- AUPH $6.55
- 52 Week High
- OPK $2.04
- AUPH $12.90
- Technical
- Relative Strength Index (RSI)
- OPK 66.28
- AUPH 64.79
- Support Level
- OPK $1.34
- AUPH $12.18
- Resistance Level
- OPK $1.44
- AUPH $12.90
- Average True Range (ATR)
- OPK 0.05
- AUPH 0.42
- MACD
- OPK 0.00
- AUPH -0.05
- Stochastic Oscillator
- OPK 97.06
- AUPH 99.25
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.